CLOV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

467.06M

+38.61%

-0.102

+155.3%

650.52M

+40.7%

0.007

-341%

667.07M

+39.66%

0.014

-168.05%

Estimates Revision

The market is revising Upward the revenue expectations for Clover Health Investments, Corp. (CLOV) for FY2025, with the revenue forecasts being adjusted by 1.26% over the past three months. During the same period, the stock price has changed by -5.24%.

Revenue Estimates for FY2025

Revise Upward

+1.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+42.93%

In Past 3 Month

Stock Price

Go Down

-5.24%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast CLOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLOV is 3.35 USD with a low forecast of 3.00 USD and a high forecast of 3.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

3.35

High

3.70

Current: 0.000

Low

3.00

Averages

3.35

High

3.70

Canaccord

Buy

downgrade

2025-11-06

Reason

Canaccord

Price Target

2025-11-06

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Clover Health to $3.70 from $4.10 and keeps a Buy rating on the shares. The firm said Clover's return to significant growth during last year's AEP and throughout 2025 when membership in its MA plans expanded rapidly finally caught up to the company in 3Q with a sizable adj-EBITDA miss and downward profitability guidance revision as elevated medical cost trend materialized in the quarter along with prior period development from 1H'25.

Canaccord

Buy

downgrade

2025-08-07

Reason

Canaccord

Price Target

2025-08-07

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50 and keeps a Buy rating on the shares. The firm said they reported solid Q2 results however the insurance benefit expense ration came in higher than expected which created some concern.

Craig-Hallum

Matt Hewitt

Buy

downgrade

$6 -> $5

2025-08-06

Reason

Craig-Hallum

Matt Hewitt

Price Target

$6 -> $5

2025-08-06

downgrade

Buy

Reason

Craig-Hallum analyst Matt Hewitt lowered the firm's price target on Clover Health to $5 from $6 and keeps a Buy rating on the shares. The firm notes the company reported strong revenue and membership growth and maintained adjusted EBITDA and adjusted net income profitability. Despite the otherwise positive update, Craih-Hallum points out that the benefits expense ratio increased for the quarter due to Part D utilization and impacts from the Inflation Reduction Act and that may weigh on the shares.

Canaccord Genuity

Richard Close

Strong Buy

Maintains

$4.2 → $4.5

2025-03-03

Reason

Canaccord Genuity

Richard Close

Price Target

$4.2 → $4.5

2025-03-03

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Clover Health Investments Corp (CLOV.O) is -30.16, compared to its 5-year average forward P/E of -11.74. For a more detailed relative valuation and DCF analysis to assess Clover Health Investments Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.74

Current PE

-30.16

Overvalued PE

-0.07

Undervalued PE

-23.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

8.16

Current EV/EBITDA

35.33

Overvalued EV/EBITDA

28.55

Undervalued EV/EBITDA

-12.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.92

Current PS

0.51

Overvalued PS

2.02

Undervalued PS

-0.18

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CLOV News & Events

Events Timeline

No data

News

8.0

01-08NASDAQ.COM

Unity Software Inc (U) Options Volume Hits 61,936 Contracts, 97.9% of Average Daily Volume

8.0

2025-12-18NASDAQ.COM

Significant Thursday Options Trading: CLOV, NNE, RUN

1.0

2025-12-16Globenewswire

Clover Health CEO Andrew Toy to Present at 2026 Healthcare Conference

People Also Watch

Frequently Asked Questions

What is Clover Health Investments Corp (CLOV) stock price today?

The current price of CLOV is 2.53 USD — it has increased 1.2 % in the last trading day.

What is Clover Health Investments Corp (CLOV)'s business?

Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a health equity-based focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. For healthcare providers outside its MA plan, it focuses on extending the benefits of its data-driven technology platform to a wider audience via its subsidiary, Counterpart Health, Inc.

What is the price predicton of CLOV Stock?

What is Clover Health Investments Corp (CLOV)'s revenue for the last quarter?

Clover Health Investments Corp revenue for the last quarter amounts to 496.65M USD, increased 50.05 % YoY.

What is Clover Health Investments Corp (CLOV)'s earnings per share (EPS) for the last quarter?

Clover Health Investments Corp. EPS for the last quarter amounts to -0.05 USD, increased 150.00 % YoY.

What changes have occurred in the market's expectations for Clover Health Investments Corp (CLOV)'s fundamentals?

How many employees does Clover Health Investments Corp (CLOV). have?

Clover Health Investments Corp (CLOV) has 570 emplpoyees as of January 09 2026.

What is Clover Health Investments Corp (CLOV) market cap?

Today CLOV has the market capitalization of 1.31B USD.